Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medtronic's Beginning Cash Position for the quarter that ended in Apr. 2026 was R$5,779 Mil.
Medtronic's quarterly Beginning Cash Position
declined
from Oct. 2025 (R$6,853 Mil) to Jan. 2026 (R$6,835 Mil) and
declined
from Jan. 2026 (R$6,835 Mil) to Apr. 2026 (R$5,779 Mil).
Medtronic's annual Beginning Cash Position
declined
from Apr. 2024 (R$7,916 Mil) to Apr. 2025 (R$7,435 Mil) but then
increased
from Apr. 2025 (R$7,435 Mil) to Apr. 2026 (R$11,170 Mil).
Medtronic Beginning Cash Position Related Terms
Medtronic Beginning Cash Position Historical Data
* Premium members only.
The historical data trend for Medtronic's Beginning Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Beginning Cash Position of R$5,779 Mil mean?
Medtronic (BSP:MDTC34) has a Beginning Cash Position of R$5,779 Mil as of Apr. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Medtronic and its competitors.
Is Medtronic's Beginning Cash Position too high?
Medtronic's current Beginning Cash Position is R$5,779 Mil. Overall, Medtronic has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medtronic's Beginning Cash Position compare to SYK and BSX?
Medtronic's Beginning Cash Position of R$5,779 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Medtronic and its competitors. Medtronic's current Beginning Cash Position is R$5,779 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Based on GuruFocus' analysis, Medtronic (BSP:MDTC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$62.06, compared to a current price of R$52.47 — trading 15.5% below its estimated fair value. The current Beginning Cash Position is R$5,779 Mil. Medtronic's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Medtronic (BSP:MDTC34), the current Beginning Cash Position is R$5,779 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medtronic (BSP:MDTC34) Overvalued in 2026?
Based on GuruFocus' analysis, Medtronic stock appears to be undervalued.
The current stock price of R$52.47 is trading 15.5% below its estimated GF Value™ of R$62.06.
GuruFocus considers Medtronic to be Modestly Undervalued.
Key valuation signals for BSP:MDTC34:
Beginning Cash Position: R$5,779 Mil
GF Value™: R$62.06 vs. price of R$52.47 (15.5% below fair value)
No single metric tells the full story. See the BSP:MDTC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
75GF Score
Get the complete analysis for BSP:MDTC34
Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:MDTC34 has been successfully added to your 
